Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table  by Kornmann, Oliver et al.
lable at ScienceDirect
Pulmonary Pharmacology & Therapeutics 28 (2014) 149e153Contents lists avaiPulmonary Pharmacology & Therapeutics
journal homepage: www.elsevier .com/locate/ypuptOmalizumab in patients with allergic (IgE-mediated) asthma and IgE/
bodyweight combinations above those in the initially approved dosing
table
Oliver Kornmann a,*,1, Henrik Watz b, Rainard Fuhr c, Norbert Krug d, Veit J. Erpenbeck e,
Guenther Kaiser e
a Pulmonary Department, Internal Medicine, University Hospital Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
b Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research,
Grosshansdorf, Germany
c PAREXEL International GmbH, Klinikum Westend, Haus 17, D-14050 Berlin, Germany
d Fraunhofer Institut für Toxikologie und Experimentelle Medizin, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany
eNovartis Pharma AG, Basel, Switzerlanda r t i c l e i n f o
Article history:
Received 8 November 2013
Received in revised form
6 March 2014
Accepted 10 March 2014
Available online 18 March 2014
Keywords:
Omalizumab
PK/PD
IgE
Bodyweight* Corresponding author. IKF Pneumologie GmbH
Centre Respiratory Diseases, Stresemannallee, 6
Tel.: þ49 (0) 69 69 59 72 580; fax: þ49 (0) 69 69 59
E-mail addresses: kornmann@ikf-pneumologie.d
pulmoresearch.de (H. Watz), Rainard.Fuhr@parexel.c
item.fraunhofer.de (N. Krug), veit.erpenbeck@nov
guenther.kaiser@novartis.com (G. Kaiser).
1 Study was undertaken while Dr. Kornmann was a
http://dx.doi.org/10.1016/j.pupt.2014.03.003
1094-5539/ 2014 The Authors. Published by Elseviea b s t r a c t
Background: When ﬁrst approved in the European Union (EU), the omalizumab dosing table had upper
bodyweight and IgE limits of 150 kg and 700 IU/mL, respectively. In this study, we assessed the safety,
pharmacokinetics (PK) and pharmacodynamics (PD) of omalizumab in patients with IgE/bodyweight
combinations above those in the original dosing table.
Methods: Amulticentre, open-label, parallel-group study assessed the safety, PK and PD of omalizumab in
32 patients with mild-to-moderate allergic (IgE-mediated) asthma. Patients received two subcutaneous
injections of omalizumab at one of three dosage levels (450, 525, or 600mg), chosen according to baseline
IgE (300e2000 IU/mL) and bodyweight (40e150 kg), with a 14-day interval between injections.
Results: Overall, 69 adverse events (AEs), none of them serious, were reported by 26 (81.3%) patients.
Analysis of laboratory measurements, vital signs and ECG data revealed no adverse ﬁndings of clinical
relevance. The PK proﬁle was consistent with previous data for lower doses. Mean maximum decrease of
free IgE from screening was 99% for all three doses, and mean free IgE concentrations remained <25 ng/
mL for at least 2 weeks after the second dose. The reductions in free IgE were consistent with levels
previously associated with clinical improvements.
Conclusions: The safety and PK/PD ﬁndings from this study are consistent with previous data, and
supported the extension of the omalizumab dosing table to include those patients with higher IgE/
bodyweight combinations.
Clinical trial registry and registration number: clinicaltrials.gov (NCT00546143).
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Omalizumab is a humanised, monoclonal anti-immunoglobulin
E (IgE) antibody, given by subcutaneous (s.c.) injection, that& Co. KG, Clinical Research
0596 Frankfurt, Germany.
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r Ltd. This is an open access articlespeciﬁcally targets and binds free IgE, reducing levels of free IgE,
while also inhibiting the binding of IgE to the high-afﬁnity IgE re-
ceptor [1]. In the European Union (EU), omalizumab is approved as
add-on therapy for the treatment of patients (age 6 years) with
severe persistent allergic (IgE-mediated) asthma that remains un-
controlled despite treatment with high-dose inhaled corticosteroid
(ICS) and a long-acting b2-agonist (LABA) [2]. The efﬁcacy and
safety of omalizumab in the treatment of severe allergic asthma
have been established through an extensive clinical trial pro-
gramme [3e6]. The original omalizumab dosing strategy was
designed to achieve a target average free IgE level of 25 ng/mL
(10.4 IU/mL; 1 IU/mL ¼ 2.4 ng/mL), and was shown to result in free
IgE levels <50 ng/mL (20.8 IU/mL) in more than 95% of patients [7].under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Omalizumab dosage, in mg, based on bodyweight and serum total IgE levels.
Bodyweight (kg) Baseline IgE (IU/mL)
Omalizumab
2  450 mg
(n ¼ 12)
Omalizumab
2  525 mg
(n ¼ 8)
Omalizumab
2  600 mg
(n ¼ 12)
>125e150 n/a >300e400 >400e2000
>90e125 >300e400 >400e500 >500e2000
>80e90 >500e600 >600e700 >700e2000
>70e80 >500e700 >700e800 >800e2000
>60e70 >600e800 >800e900 >900e2000
>50e60 >700e900 >900e1000 >1000e2000
>40e50 >900e1100 >1100e1300 >1300e2000
The ﬁrst dose of omalizumab was administered on Day 1 and the second dose on
Day 15.
IgE ¼ Immunoglobulin E; n/a ¼ not applicable.
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The appropriate omalizumab dosage and dosing and schedule
are determined by the patient’s bodyweight (kg) and baseline total
IgE levels (IU/mL). When initially approved, omalizumab was
indicated for patients with a bodyweight of >20e150 kg and an IgE
level of30e700 IU/mL, and the highest dosewas 375mg s.c. every
two weeks. However, clinical data from the INNOVATE (Phase III
pivotal trial of omalizumab) and TENOR studies indicated that up to
one-third of patients, or more, had baseline IgE/bodyweight com-
binations that fell above those in the dosing table, e.g. >600 IU/mL/
>60 kg, >500 IU/mL/>70 kg and >300 IU/mL/>90 kg. These pa-
tients would require higher omalizumab doses than 375 mg every
two weeks [5,8,9].
This study is one of two studies (the other being a recently
published allergen bronchoprovocation study [10]) that were
carried out according to an European Medicines Agency (EMA)
post-approval commitment to evaluate the safety, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of omalizu-
mab in asthma patients with baseline IgE/bodyweight combi-
nations above those in the original dosing table. Following
evaluation of these studies by EMA, the omalizumab dosing table
was expanded to include patients with an IgE level up to
1500 IU/mL, and omalizumab doses up to 600 mg every two
weeks [2].
2. Methods
2.1. Study design and patients
This was a multicentre, open-label, multi-dose study in patients
with mild-to-moderate allergic asthma. Non-smoking male or fe-
male (negative pregnancy test required) patients, 18e55 years old
with baseline bodyweight ranging from 40 to 150 kg and serum IgE
levels of 300e2000 IU/mL, were enrolled in the study. Patients
were eligible for inclusion if they had been diagnosed with allergic
asthma 1 year before screening, and were receiving treatment
consistent with GINA step 2 or 3 (mild or moderate persistent
asthma) [11].
Key exclusion criteria included: a history of anaphylaxis; lung
disease other than mild-to-moderate allergic asthma; a smoking
history of10 pack-years or use of inhaled tobacco products within
the last 12 months; oral corticosteroid (OCS) or investigational
small molecule drug use within the last 3 months; monoclonal
antibody use in the previous 6 months; exacerbation requiring
either an emergency room visit within 6 weeks prior to or during
screening; intubation and mechanical ventilation in the previous
12 months; or respiratory tract infection within the 4 weeks prior
to the ﬁrst dose.
The study was designed, implemented and reported in accor-
dance with Good Clinical Practice, local regulations, and the ethical
principles of the Declaration of Helsinki. This study is registered on
clinicaltrials.gov (NCT00546143).
2.2. Treatment
Patients were randomised to one of three omalizumab dose
groups (2  450 mg, 2  525 mg or 2  600 mg) according to their
baseline IgE level and bodyweight (Table 1). Each patient received
two doses of omalizumab by subcutaneous injection; the ﬁrst dose
on Day 1 and the second on Day 15. The doses were selected based
on the following criteria; the original dosing algorithm of
0.016 mg omalizumab per kg bodyweight, per IU/mL baseline IgE,
per 4 weeks was applied [12,13]. If the resulting dose would have
required more than 4 individual injections, the dose was restrictedto 600 mg as the maximum dose per injection is 150 mg [2]. The
ﬁrst condition was met for the 2  450 mg and 2  525 mg dose
groups. The second condition applied to the 2  600 mg dose
group.
Patients were permitted to continue with existing medications
for the treatment of asthma if their asthma had been stable for 3
months before screening.
2.3. Study assessments and data analysis
Safety assessments were conducted for vital signs, standard
clinical laboratory evaluations, anti-omalizumab antibodies,
adverse events (AEs) and serious AEs (SAEs). The safety population
comprised all patients who received at least one dose of omalizu-
mab and had at least one post-baseline safety assessment.
Descriptive statistics for the safety population were provided by
treatment group.
Serum samples for PK and PD evaluations were collected pre-
dose, at 12 h post-dose on Day 1, and thereafter on Day 2 (24 h
post-dose), and on Days 3, 4, 6, 8, 11, 15 (pre-second dose), 16 (24 h
after second dose), and on Days 17, 18, 20, 22, 25, 29, 36, 43, 57, 71,
85 and 99.
Total omalizumab concentrations in serum were measured
by a speciﬁc and validated ELISA method, as described previ-
ously [10]. The following PK parameters were derived from the
concentrationetime proﬁles of omalizumab between Day 1 and
Day 99 (the two doses were not separated for the PK analysis):
area under the serum concentrationetime curve AUClast
(AUC up to the last quantiﬁable concentration), AUCinf (AUC
extrapolated to inﬁnity), Cmax (maximum concentration after
the second dose), Tmax (the time to Cmax), T1/2 (terminal half-
life), and CL/F (apparent total body clearance). PK parameters
were determined by non-compartmental methods with
WinNonlin Professional (Version 5.2, Pharsight, Palo Alto,
California, USA).
Serum levels of free IgE and total IgE (i.e. the sum of free and
bound IgE) were determined by speciﬁc immunoassays, as
described previously [10]. PD parameters were determined after
both the ﬁrst and the second omalizumab dose. For free serum IgE,
Cmin (the minimum concentration), Tmin (time to Cmin), and the
maximum percent decrease from screening were determined. For
total IgE, Cmax, Tmax and the maximum percent increase from
screening were determined.
In the PK/PD analyses, only patients with evaluable PK/PD data
were included. Descriptive statistics for PK and PD parameters per
treatment group included median and range for Tmax and Tmin,
respectively, and arithmetic mean and standard deviation for all
other parameters.
Table 3
Overall and most frequently reported AEs, experienced by at least two patients.
Omalizumab
2  450 mg
(n ¼ 12)
Omalizumab
2  525 mg
(n ¼ 8)
Omalizumab
2  600 mg
(n ¼ 12)
Overall
(n ¼ 32)
Patients with AEs, n (%) 11 (91.7) 7 (87.5) 8 (66.7) 26 (81.3)
Headache 5 (41.7) 3 (37.5) 3 (25.0) 11 (34.4)
Nasopharyngitis 1 (8.3) 2 (25.0) 4 (33.3) 7 (21.9)
Bronchitis 2 (16.7) 0 (0.0) 1 (8.3) 3 (9.4)
Abdominal pain 1 (8.3) 0 (0.0) 1 (8.3) 2 (6.3)
Gastroenteritis 2 (16.7) 0 (0.0) 0 (0.0) 2 (6.3)
Back pain 1 (8.3) 1 (12.5) 0 (0.0) 2 (6.3)
Pain in extremity 1 (8.3) 0 (0.0) 1 (8.3) 2 (6.3)
Dysmenorrhoea 1 (8.3) 0 (0.0) 1 (8.3) 2 (6.3)
Pharyngolaryngeal pain 1 (8.3) 0 (0.0) 1 (8.3) 2 (6.3)
The ﬁrst dose of omalizumab was administered on Day 1 and the second dose on
Day 15.
AE ¼ adverse event.
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3.1. Patient demographics and baseline characteristics
Overall, 32 patients were enrolled and 31 completed the study.
Two patients (both in the 600 mg group) were not included in the
PK analysis (one was lost to follow-up and one did not receive the
complete second dose, i.e. only 500 mg instead of 600 mg). Patient
demographics and baseline characteristics are shown in Table 2.
3.2. Safety
Table 3 shows the most frequently reported AEs (occurring in
two or more patients). Overall, 26/32 (81.3%) patients reported 69
AEs, 10 of which (6 patients) were considered by the investigators
to be omalizumab-related. Most of the AEs reported in this study
were related to the underlying disease and to patients’ general
health. Two asthma exacerbations (one on study day 3 and one on
study day 73, each of moderate severity) were observed in one
subject in the 600 mg dose group. Three events of bronchitis were
distinct from these asthma exacerbations and observed in three
different subjects (two subjects from the 450 mg dose group and
one subject from the 600mg dose group). The AEs suspected by the
investigator to be treatment related were: headache and haema-
toma under the toenails (in the 450 mg dose group); diarrhoea,
nausea, vomiting, headache, and pruritus (in the 525 mg dose
group); and headache, abdominal pain, and sore throat (in the
600 mg dose group). Most AEs were considered to be mild or
moderate, transient, and not dose-related. One AE (pain in the right
calf) was reported as severe, but not omalizumab-related. There
were no deaths or SAEs reported during the study, no unexpected
AEs, and no patients discontinued the study because of an AE.
Laboratory measurements, levels of anti-omalizumab anti-
bodies, vital signs, ECG recordings and spirometric results did not
reveal any clinically relevant adverse ﬁndings or trends that were
potentially related to omalizumab treatment.
3.3. Pharmacokinetics
After the ﬁrst dose, serum omalizumab concentrations slowly
increased and reached peak values 2e10 days after administration,
regardless of dosage. Following the second dose on Day 15, oma-
lizumab concentrations increased further and reached overall peak
values a couple of days later (Fig. 1a). The mean terminal half-life of
omalizumabwas around 20 days (range of means for the three dose
groups: 18e22 days; Table 4). The mean apparent CL/F of omali-
zumab was 6.9e9.2 mL/h. Omalizumab total exposure as assessedTable 2
Patient demographics and baseline characteristics by treatment group.
Omalizumab
2  450 mg
(n ¼ 12)
Omalizumab
2  525 mg
(n ¼ 8)
Omalizumab
2  600 mg
(n ¼ 12)
Overall
(n ¼ 32)
Age, years Mean
(range)
34.9
(22e46)
33.1
(18e50)
37.3
(21e52)
35.4
(18e52)
Male n (%) 6 (50.0) 5 (62.5) 9 (75.0) 20 (62.5)
Caucasian n (%) 11 (91.7) 7 (87.5) 11 (91.7) 29 (90.6)
Bodyweight, kg Mean
(range)
84.6
(62e105.5)
80.5
(50e98)
84.0
(68.6e95.5)
83.0
(50e105.5)
Total IgE at
screening,
Mean (SD)
IU/mL
ng/mL
503 (143)
1207 (343)
670 (202)
1608 (485)
989 (205)
2374 (492)
727 (280)
1745 (672)
1 IU/mL of IgE is equivalent to 2.4 ng/mL.
The ﬁrst dose of omalizumab was administered on Day 1 and the second dose on
Day 15.
IgE ¼ immunoglobulin E; SD ¼ standard deviation.by AUCinf was in the same range for the three dose groups. The
mean exposure after the 2  600 mg doses was slightly lower than
after 2  525 mg doses, but in proportion to the 2  450 mg doses.
Similarly, the peak exposure as expressed by mean Cmax was
highest after the 2  525 mg doses, whereas the increase in Cmax
following 2  600 mg was in approximate proportion to the in-
crease in dose from 2  450 mg (Table 4).
3.4. Pharmacodynamic analysis
In all three dose groups, omalizumab reduced the level of free IgE
by99% after the ﬁrst dose (Fig. 1b). The mean (SD) Cmin of free IgE
was 11.85 (2.40),11.79 (2.73) and 16.56 (3.66) ng/mL for the 450mg,
525 mg and 600 mg dose groups, respectively, and was reached
between 2 and 3 days (median Tmin). IgE levels then increased
slightly until pre-second dose on Day 15 in all three groups.
Following the second dose, IgE levels declined for a second time; the
second mean (SD) Cmin was 12.09 (2.30), 12.18 (2.65) and 16.26
(5.09) ng/mL for the 450, 525, and 600mgdose groups, respectively,
and occurred between 4 and 5 days (median Tmin) after the second
dose. Themaximum percentage decrease of IgE from screening was
similar between the three groups, and between the ﬁrst and second
doses (range of means: 99.0e99.3%). Mean free IgE levels remained
<25 ng/mL for at least 2 weeks after the second dose.
Total IgE levels increased in all three dose groups up to 14 days
after the ﬁrst dose, and continued to increase after the second dose,
reaching a peak between 21 and 28 days (median Tmax) after the
second dose (data not shown). Total IgE levels were still elevated on
study day 99 in all dose groups. Cmax of total IgE increased in a dose-
dependent manner. Mean (SD) Cmax after the second dose was 4511
(1378), 5243 (1621) and 6058 (1368) ng/mL for the 2  450 mg,
2  525 mg and 2  600 mg dose groups, respectively, reﬂecting
both the increase of the omalizumab dose and the parallel increase
of baseline IgE values (Table 1). The mean maximum percentage
increase in total IgE from screening was 281, 242 and 159%,
respectively.
4. Discussion
This clinical study was primarily designed to meet an EMA post-
approval commitment regarding the safety and tolerability, PK and
PD of omalizumab in patients with mild-to-moderate asthma with
baseline IgE/bodyweight combinations above those deﬁned in the
initially approved dosing table. It was expected that safety, tolera-
bility, PK and PD data from the present clinical study would be
consistent with existing or modelled data; and, if efﬁcacy could be
conﬁrmed in a separate study, that this would allow for an
Fig. 1. Arithmetic mean concentrationetime proﬁles of serum omalizumab (a), and
free IgE (b) following a ﬁrst dose on Day 1 and a second dose on Day 15. All individual
values of free IgE were above the upper limit of quantiﬁcation (150 ng/ml) and were
therefore set to 150 ng/mL, resulting in a mean (SD) value of 150 (0.0) ng/mL for all
pre-dose assessments on Day 1.
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extended range of asthma patients to receive omalizumab. The
rationale for this request was that a substantial number of patients
had IgE levels above those in the initial dosing table (INNOVATE [5]
and TENOR [9]). Consequently, it was hypothesised that patients
with higher IgE levels (>700 IU/mL at baseline) would beneﬁt from
the extension of the initially approved dosing table if their IgE was
suppressed to a level previously shown to be correlated with clin-
ical efﬁcacy.
Patients with mild-to-moderate allergic asthma with increased
IgE levels were selected, but the conclusions drawn from the PD
response were used for a dosing table expansion for uncontrolled
severe allergic asthma patients, in accordance with the omalizu-
mab label.Table 4
Pharmacokinetic parameters of omalizumab following a ﬁrst dose on Day 1 and a
second dose on Day 15.
PK parameter Omalizumab
2  450 mg
(n ¼ 12)
Omalizumab
2  525 mg
(n ¼ 8)
Omalizumab
2  600 mg
(n ¼ 10)
AUClast, day.mg/mL 4347 (843) 6228 (1535) 5692 (1744)
AUCinf, day.mg/mL 4602 (944) 6666 (1570) 5946 (1910)
Cmax, mg/mL 121.9 (53.2) 161.2 (30.4) 148.1 (38)
Tmax, day 20.0 (15.0e24.1) 19.0 (15.0e24.0) 17.0 (15.0e21.0)
T1/2, day 19.9 (2.7) 21.6 (2.9) 17.6 (3.8)
CL/F, mL/h 8.49 (1.84) 6.90 (1.64) 9.18 (2.77)
Values are median (range) for Tmax, and arithmetic mean (SD) for all other param-
eters.
AUC ¼ area under the serum concentrationetime curve; AUClast ¼ AUC
up to the last quantiﬁable concentration; AUCinf ¼ AUC extrapolated to inﬁnity;
CL/F ¼ apparent total body clearance; Cmax ¼ maximum concentration;
SD ¼ standard deviation; T1/2 ¼ terminal half-life; Tmax ¼ time to Cmax.As observed after the administration of lower doses of omali-
zumab [12], serum omalizumab concentrations slowly increased to
reach maximum concentrations a few days after administration, i.e.
3e6 days (median values) after the second dose. Thereafter, oma-
lizumabwas eliminated with a mean T1/2 around 20 days. This half-
life is similar to values seen previously in subjects with IgE values
between 30 and 300 IU/mL after a single omalizumab dose of
150 mg or 300 mg (mean T1/2 was 22e23 h) [14]. A mean apparent
clearance of omalizumab of 2.4 mL/kg/day was reported for asthma
patients [2]. For a patient with a bodyweight of 80 or 85 kg (within
the range of mean bodyweight in our study; Table 2), this translates
into a CL/F value of 192 mL/day and 204 mL/day, respectively, or
8.0 mL/h and 8.5 mL/h, respectively. These values are within the
range of mean values reported in our study (Table 4).
Overall, the PK and PD proﬁles of omalizumab were consistent
with existing data [2,12]. Omalizumab concentrations increased
after the ﬁrst and second doses, reaching overall peak values after
the second dose. All omalizumab doses reduced free IgE concen-
trations by at least 99.0%, a magnitude of reduction that has been
associated with improvements in clinical symptoms [15]. Mean free
IgE levels remained <25 ng/mL for at least 2 weeks after admin-
istration of the second dose. These data suggest that patients with
IgE levels higher than 700 IU/mL might be effectively treated with
omalizumab.
The inclusion criteria in this study allowed to enrol patients with
baseline IgE levels up to 2000 IU/mL (Table 1). In the ﬁnal extended
dosing table approved in the EU, the upper limit of baseline IgE is
1500 IU/mL for patients with a bodyweight up to 50 kg, and de-
creases bodyweight-dependent in steps for bodyweights between
50 and 150 kg [2]. This ensures that doses for all bodyweighte
baseline IgE combinations adhere to the original dosing algorithm
of 0.016 mg omalizumab per kg bodyweight, per IU/mL baseline
IgE, per 4 weeks. Patients exposed to omalizumab dosed according
to this algorithm showed reductions of free IgE to the range of 10e
20 ng/mL, a level which was previously linked to clinical efﬁcacy in
asthma endpoints [12].
Omalizumab was well tolerated during this study; the safety
ﬁndings were consistent with the known safety proﬁle of omali-
zumab at lower doses [4]. However, this was a short-term study of
only two doses, whereas real-world use of omalizumab is typically
long-term. This study was not designed to assess efﬁcacy. A further
limitation of the study was the small number of patients assessed;
this may explain the variations observed in PK and PD values. The
results of this study were similar to a corresponding efﬁcacy study,
which demonstrated that patients with higher baseline IgE levels
treated with omalizumab for 16 weeks experienced a signiﬁcant
reduction in early-phase allergic response compared with patients
receiving placebo [10]. The safety and PK/PD ﬁndings from this
study are consistent with previous trial data and support the
extension of the initially approved omalizumab dosing table to
patients with baseline IgE levels >700 IU/mL.
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